Deutsche Bank
SRPT icon

Deutsche Bank’s Sarepta Therapeutics SRPT Stock Holding History

Deutsche Bank’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,650
Closed -$91K – 5589
2017
Q4 		$91K Hold
1,650
– – ﹤0.01% 4279
2017
Q3 		$74K Hold
1,650
– – ﹤0.01% 4263
2017
Q2 		$55K Hold
1,650
– – ﹤0.01% 4355
2017
Q1 		$48K Buy
+1,650
New +$51.1K ﹤0.01% 4239

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deutsche Bank's SRPT Position: Q2 2026 in Review

Deutsche Bank increased its Sarepta Therapeutics (SRPT) stake by 795% in Q2 2026, buying an estimated $1.91M and bringing the position to 113,724 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1898.

Deutsche Bank first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $249M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Deutsche Bank held 113,724 shares of Sarepta Therapeutics worth $2.04M as of Q2 2026.
  • Deutsche Bank bought 101,024 Sarepta Therapeutics shares in Q2 2026, an estimated $1.91M.
  • Sarepta Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1898 holding.
  • Deutsche Bank first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Sarepta Therapeutics position peaked at $249M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.